12/2
03:47 pm
xlo
Xilio Therapeutics (NASDAQ:XLO) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Xilio Therapeutics (NASDAQ:XLO) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/26
02:24 pm
xlo
Xilio Therapeutics (NASDAQ:XLO) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Xilio Therapeutics (NASDAQ:XLO) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/13
07:30 am
xlo
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results
Medium
Report
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results
11/11
04:06 am
xlo
Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC Transcript [Seeking Alpha]
Medium
Report
Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC Transcript [Seeking Alpha]
11/7
09:05 am
xlo
Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
High
Report
Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
11/7
09:01 am
xlo
Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
Medium
Report
Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
11/3
04:30 pm
xlo
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/30
09:35 am
xlo
Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting [Yahoo! Finance]
Medium
Report
Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting [Yahoo! Finance]
10/30
09:01 am
xlo
Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting
Low
Report
Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting
10/24
12:26 pm
xlo
Xilio Therapeutics (NASDAQ:XLO) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Xilio Therapeutics (NASDAQ:XLO) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/8
12:39 pm
xlo
Xilio Therapeutics (NASDAQ:XLO) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Xilio Therapeutics (NASDAQ:XLO) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/6
09:34 am
xlo
Preclinical Advanced Cell Models Market Segmentations and Regional Focused Report (2025 – 2034) [Yahoo! Finance]
Low
Report
Preclinical Advanced Cell Models Market Segmentations and Regional Focused Report (2025 – 2034) [Yahoo! Finance]
10/3
03:48 pm
xlo
Xilio Therapeutics (NASDAQ:XLO) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Xilio Therapeutics (NASDAQ:XLO) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/3
09:12 am
xlo
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting [Yahoo! Finance]
Medium
Report
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting [Yahoo! Finance]
10/3
09:00 am
xlo
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
Medium
Report
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
10/2
04:36 pm
xlo
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Medium
Report
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
10/2
04:30 pm
xlo
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/9
08:03 am
xlo
Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead [Yahoo! Finance]
Low
Report
Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead [Yahoo! Finance]
9/9
07:30 am
xlo
Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead
Low
Report
Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead